Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine Effect on Mirdametinib Pharmacokinetics in Healthy Participants
NCT07279233Phase 1Completed
- Sponsor
- SpringWorks Therapeutics
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mirdametinib (2 arms), sponsored by SpringWorks Therapeutics. Primary endpoints: Area Under the Concentration-Time Curve from Dosing Extrapolated to Infinity, Area Under the Concentration-Time Curve from Dosing to Time of Last Quantifiable Concentration and 1 more. Started Dec 2025; status: completed.
02
Drugs
mirdametinib
Beyond the preview
Go deeper on NCT07279233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279233.